Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
Dan‐Yun Ruan(Sun Yat-sen University), Rui‐Hua Xu(Sun Yat-sen University), Gary Richardson(Cabrini Hospital), Yanhong Deng(Sun Yat-sen University), Seok Jae Huh(Dong-A University Hospital), Myung Ah Lee(The Catholic University of Korea Seoul St. Mary's Hospital), Shirish M. Gadgeel(Chinese University of Hong Kong), Shaozhong Wei(Hubei Cancer Hospital), Ling Zhang(Qinghai University), Furong Liu(Sun Yat-sen University), Ziyong Xiang, Jaspreet Singh Grewal(Norton Healthcare), Michael Millward(The University of Western Australia), Keun‐Wook Lee(Seoul National University Bundang Hospital), Xiaoxi Xie, Zhe Shi(National University of Singapore), Yaolin Wang, Xinfang Hou(Zhengzhou University), Rachel E. Sanborn(Providence Portland Medical Center)
Cited by 12
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k